Updated data from Caribou Biosciences, Inc.’s Phase I ANTLER trial of its off-the-shelf CD19-directed CAR-T cell therapy, CB-010, show better results than before in terms of durability of response among patients with large B-cell lymphoma (LBCL) and other B-cell non-Hodgkin lymphomas (NHL), although the numbers remain small. The company is moving ahead to determine a recommended Phase II dose.
Caribou announced the updated data on 13 July for all 16 patients treated in the dose-escalation portion of ANTLER, 10 of whom had LBCL, with three dose levels – 40 million, 80 million and 120 million cells – across multiple NHL subtypes